$IOVA SEC Filings

Filed On	Filing
05 Oct 2026	8-K: Other Events 1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1
02 Oct 2026	Form 4: Berkowitz Noah, Chief Medical Officer Granted 135,000 Stock Options (Right to Buy) · Granted 180,000 Restricted Stock Units · Granted 135,000 Performance Stock Units
02 Oct 2026	Form 3: Berkowitz Noah, Chief Medical Officer No securities owned
29 Sep 2026	8-K: Other Events New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million
10 Sep 2026	Form 4: Vogt Frederick G, Director Received 15,626 shares by exercise or conversion · Gave up 6,638 shares to cover exercise price or tax ($57.8K)
10 Sep 2026	Form 4: Bilinsky Igor, Chief Operating Officer Received 7,813 shares by exercise or conversion · Gave up 3,976 shares to cover exercise price or tax ($34.6K)
10 Sep 2026	Form 4: Puri Raj K., Chief Regulatory Officer Received 9,766 shares by exercise or conversion · Gave up 4,478 shares to cover exercise price or tax ($39K)
03 Sep 2026	Form 4: Vogt Frederick G, Director Received 41,669 shares by exercise or conversion · Gave up 17,702 shares to cover exercise price or tax ($147K)
03 Sep 2026	Form 4: Puri Raj K., Chief Regulatory Officer Received 5,470 shares by exercise or conversion · Gave up 2,508 shares to cover exercise price or tax ($20.8K)
03 Sep 2026	Form 4: Bilinsky Igor, Chief Operating Officer Received 8,789 shares by exercise or conversion · Gave up 4,472 shares to cover exercise price or tax ($37K)
12 Aug 2026	Form 4: Kirby Daniel Gordon, Chief Commercial Officer Received 10,001 shares by exercise or conversion · Gave up 2,436 shares to cover exercise price or tax ($15.6K)
10 Aug 2026	Form 4: Roche Corleen M., Chief Financial Officer Received 49,995 shares by exercise or conversion · Gave up 21,238 shares to cover exercise price or tax ($132K)
07 Aug 2026	SCHEDULE 13G
06 Aug 2026	8-K: Other Events
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
28 Jul 2026	SCHEDULE 13G/A
02 Jul 2026	8-K: Other Events
18 Jun 2026	Form 4: Weiser Michael, Director Granted 90,316 Deferred Restricted Stock Unit
18 Jun 2026	Form 4: Dukes Iain D., Director Granted 180,632 Deferred Restricted Stock Unit

Comments